| Literature DB >> 12634972 |
Claudia M Szobot1, Carla Ketzer, Renato D Cunha, Maria A Parente, Daniel D Langleben, Paul D Acton, Flávio Kapczinski, Luis A P Rohde.
Abstract
Methylphenidate (MPH) is the most commonly prescribed treatment for attention-deficit/hyperactivity disorder (ADHD). The therapeutic mechanisms of MPH are not, however, fully understood. We studied the effects of MPH on brain activity in male children and adolescents with ADHD, using the blood flow radiotracer technetium-99m ethyl cysteinate dimer ((99m)Tc-ECD) and single-photon emission tomography (SPET). The study was randomized, double blind, and placebo controlled (MPH group, n=19; placebo group, n=17), Radiotracer was administered during the performance of the Continuous Performance Test and before and after 4 days of MPH treatment. Statistical parametric mapping (SPM99) analysis showed a significant reduction in regional cerebral blood flow in the left parietal region in the MPH group compared with the placebo group (P<0.05, corrected for multiple comparisons). Our findings suggest that the posterior attentional system, which includes the parietal cortex, may have a role in the mediation of the therapeutic effects of MPH in ADHD.Entities:
Mesh：
Substances：
Year: 2003 PMID： 12634972 DOI： 10.1007/s00259-002-1082-0
Source DB: PubMed Journal: Eur J Nucl Med Mol Imaging ISSN： 1619-7070 Impact factor: 9.236